Trial results show no survival benefit with the use of proton therapy in patients with advanced hepatocellular carcinoma

Initial results of the NRG Oncology NRG-GI003 objective survey comparing proton and photon therapy for patients with precocious hepatocellular carcinoma (HCC) bespeak that proton therapy did not amended the superior nonsubjective of wide endurance (OS). At the planned interim analysis, the proceedings was released for reporting aft it crossed the futility boundary. Proton therapy besides did not amended the trial's secondary endpoints, including progression-free endurance (PFS) and section progression (LP).